Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ALTAREX CORP. (TSE: AXO) -- Ignore unavailable to you. Want to Upgrade?

To: Mark J. Redmond who wrote (243)	10/20/2000 11:57:25 AM
From: Mark J. Redmond	Respond to of 274

Updating public announcements - note the dates in the following announcement from earlier this month as well as links to other websites AltaRex Corp. presents additional preclinical data for its lead antibody, OvaRex(TM) for ovarian cancer. This preclinical data, combined with experience gained in the clinic to date, demonstrate a consistent mechanism supporting the correlation between OvaRex(TM) MAb induced immune response and clinical benefit. The Company is presenting at Cancer Vaccine 2000 in New York City results from preclinical studies of both its OvaRex(TM) (ovarian cancer) and ProstaRex(TM) (prostate cancer) antibodies. In the Company's preclinical dendritic cell model, immune complexes appear to modify antigen presentation for priming of the cellular responses necessary to effect tumor killing. Antigen or antibody alone appear not to induce cellular immunity. Further, human anti-mouse antibody (HAMA) appears to augment this antigen presentation process, a premise that contradicts the traditional view that the induction of HAMA would block the clinical effect. The Company's novel immunological work has resulted in a unique way to use low dose foreign antibodies that complex with antigen directly in the bloodstream. Uptake of this complex by antigen presenting cells can be enhanced by the presence of HAMA. It is these findings that form the basis of a number of pending patent applications by the Company. The Company has consistently seen in OvaRex(TM) clinical results to date a correlation between HAMA induction and an impact on clinical effect. In line with these findings, the Company has recently begun enrollment, as planned, in a new open randomized trial in the "watchful waiting" indication of ovarian cancer that is expected to demonstrate that the clinical benefit seen to date derives from a specific OvaRex (TM)-directed immune response. This trial will be supportive of the ongoing lead 345 patient double-blind placebo-controlled trial in "watchful waiting" that has already evidenced, in an interim analysis, a benign safety profile and a correlation of HAMA induction with clinical effect. This HAMA correlation has also been observed and reported in the Company's phase II trials of OvaRex(TM) MAb in recurrent ovarian cancer, where it has traditionally been believed that patients whose immune systems have already been compromised from chemotherapy would be unable to mount a meaningful immune response of any kind. In addition to this scientific meeting and the recent Stephens Inc. Anti-Cancer Conference in San Francisco (September 19), the Company is presenting at several other upcoming investor conferences. These conferences include BioContact Quebec (October 5), Mass Opportunities in Boston (October 19), the EC-21 Conference in London (October 19), and CIBC World Markets Health Care Conference in New York (October 23). Additional information about AltaRex research and development, news and events can be found on its web site at www.altarex.com. Clinical information can also be found on the CenterWatch web site at www.centerwarch.com. Additional information about ovarian cancer can be found at www.ovariancanada.org and at www.ovarian.org.